Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
JANX is expected to report earnings to fall 20.64% to -30 cents per share on August 11
Q2'26
Est.
$-0.31
Q1'26
Beat
by $0.18
Q4'25
Beat
by $0.11
Q3'25
Beat
by $0.23
Q2'25
Missed
by $0.09
The last earnings report on May 07 showed earnings per share of -38 cents, beating the estimate of -56 cents. With 931.72K shares outstanding, the current market capitalization sits at 801.33M.